Matthew D. Hellmann
Memorial Sloan Kettering Cancer Center(US)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer(2015)7,863 cited
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,153 cited
- → Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors(2017)5,249 cited
- → Immune-Related Adverse Events Associated with Immune Checkpoint Blockade(2018)4,500 cited
- → Tumor mutational load predicts survival after immunotherapy across multiple cancer types(2019)4,299 cited
- → Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients(2017)3,455 cited
- → Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden